Related Experiment Video
Updated: Jun 26, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Review article: investigational agents for chronic hepatitis C
A J V Thompson1, J G McHutchison
1Division of Gastroenterology/Hepatology, Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA.
Alimentary Pharmacology & Therapeutics
|February 3, 2009
Summary
New antiviral therapies for chronic hepatitis C infection are emerging, offering higher cure rates and shorter treatment durations. These promising treatments face challenges like drug resistance and toxicity.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C virus (HCV) infection necessitates the development of effective antiviral treatments.
- Novel agents targeting specific viral replication steps are crucial for advancing HCV therapy.
Purpose of the Study:
- To review current literature on investigational agents for chronic hepatitis C virus infection.
- Focus on agents that have advanced beyond preclinical development.
Main Methods:
- Literature search of PubMed and major liver association conference proceedings (2005-2008).
- Inclusion of data from the National Institute of Health's clinical trials website.
- Selection criteria focused on agents in clinical development.
Main Results:
- Over 50 investigational agents are in clinical development for chronic hepatitis C.
- Specifically Targeted Anti-Viral Therapy for HCV (STAT-C), including NS3/4a protease inhibitors, shows significant promise.
- New formulations of interferon-alpha and ribavirin aim to improve efficacy and reduce toxicity; immunomodulators and vaccines are also under investigation.
Conclusions:
- A new era of hepatitis C therapy is approaching, with potential for increased cure rates and shorter treatment durations.
- Challenges include managing viral resistance, drug toxicity, and optimizing combination therapies.
- The evolving therapeutic landscape requires careful management for successful chronic hepatitis C treatment.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...